Hypoxia-induced mediators and neurologic disease
暂无分享,去创建一个
[1] J. Bartek,et al. Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay , 2008, Cell cycle.
[2] M. Fernando,et al. Expression of Vascular Endothelial Growth Factor and Its Receptors in the Central Nervous System in Amyotrophic Lateral Sclerosis , 2006, Journal of neuropathology and experimental neurology.
[3] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[4] L. Defebvre,et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[5] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[6] H. Ehrenreich,et al. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[7] W. Kaelin. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.
[8] H. Brismar,et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection , 2009, Proceedings of the National Academy of Sciences.
[9] C. Taylor. Mitochondria and cellular oxygen sensing in the HIF pathway. , 2008, The Biochemical journal.
[10] Ling Wei,et al. Therapeutic strategy of erythropoietin in neurological disorders. , 2008, CNS & neurological disorders drug targets.
[11] R. D'Hooge,et al. Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration , 2008, The Journal of Neuroscience.
[12] J. Gidday. Cerebral preconditioning and ischaemic tolerance , 2006, Nature Reviews Neuroscience.
[13] U. Dirnagl,et al. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use , 2009, The Lancet Neurology.
[14] D. Geschwind,et al. Small Molecule Activation of Adaptive Gene Expression , 2008, Annals of the New York Academy of Sciences.
[15] W. Kaelin,et al. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.
[16] E. Mackenzie,et al. Normobaric Hypoxia Induces Tolerance to Focal Permanent Cerebral Ischemia in Association with an Increased Expression of Hypoxia-Inducible Factor-1 and its Target Genes, Erythropoietin and VEGF, in the Adult Mouse Brain , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.
[18] G. Pignataro,et al. Post‐ischemic brain damage: effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy , 2009, The FEBS journal.
[19] J. Chávez,et al. Mitochondria and Hypoxia‐induced Gene Expression Mediated by Hypoxia‐inducible Factors , 2008, Annals of the New York Academy of Sciences.
[20] A. Zepeda,et al. Vascular Endothelial Growth Factor Prevents Paralysis and Motoneuron Death in a Rat Model of Excitotoxic Spinal Cord Neurodegeneration , 2007, Journal of neuropathology and experimental neurology.
[21] Ulrich Dirnagl,et al. Ischemic tolerance and endogenous neuroprotection , 2003, Trends in Neurosciences.
[22] Frank M. Sacks,et al. IDH 1 and IDH 2 Mutations in Gliomas , 2009 .
[23] A. Cerami,et al. Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.
[24] Y. Itoyama,et al. Development of a high-throughput microarray-based resequencing system for neurological disorders and its application to molecular genetics of amyotrophic lateral sclerosis. , 2008, Archives of neurology.
[25] Xiaowen Zhang,et al. Mutant copper‐zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine‐rich stability elements in the vascular endothelial growth factor 3′‐untranslated region , 2009, Journal of neurochemistry.
[26] Myriam Bernaudin,et al. Hypoxic preconditioning protects against ischemic brain injury , 2011, NeuroRX.
[27] C. Thompson,et al. Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.
[28] W. Robberecht,et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2 , 2010, Neurobiology of Aging.
[29] A. Gregory Sorensen,et al. Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.
[30] H. Ehrenreich,et al. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system , 2011, Neurotherapeutics.
[31] K. Stevens,et al. VEGF and osteosclerosis in POEMS syndrome , 2008, Annals of Hematology.
[32] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[33] H. H. Marti,et al. Erythropoietin and the hypoxic brain , 2004, Journal of Experimental Biology.
[34] M. Hussein,et al. Central nervous system capillary haemangioblastoma: the pathologist's viewpoint , 2007, International journal of experimental pathology.
[35] F. Groenendaal,et al. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia , 2008, Brain Research Reviews.
[36] H. H. Marti,et al. Brain protection by erythropoietin: a manifold task. , 2008, Physiology.
[37] G. Condorelli,et al. Vascular endothelial growth factors in cardiovascular medicine , 2008, Journal of cardiovascular medicine.
[38] R. Johnson,et al. Nonrenal regulation of EPO synthesis. , 2009, Kidney international.
[39] J. LaManna,et al. Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition , 2005, Journal of Biological Chemistry.
[40] G. Olmos,et al. Vascular endothelial growth factor protects motoneurons from serum deprivation–induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition , 2009, Neuroscience.
[41] M. Bernaudin,et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: Identification of potential neuroprotective candidates for stroke , 2006, Neurobiology of Disease.
[42] S. Sathasivam. VEGF and ALS , 2008, Neuroscience Research.